Clinical Trials Details

E4512 ALCHEMIST - SUBSTUDY (Lung)

Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Objective

Key eligibility: ALK+ patients; Stage IB/II/IIIA NSCLC; R0; registered to A151216.

» Learn more about this trial

Clinical Trial Categories

  • Cancers and Other Neoplasms